Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

This study has been completed.
Sponsor:
Information provided by:
Sirion Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00502073
First received: July 13, 2007
Last updated: June 29, 2011
Last verified: June 2011

July 13, 2007
June 29, 2011
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00502073 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
Not Provided

The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Dry Eye Syndromes
Drug: cyclosporine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of moderate to severe dry eye syndrome with or without Sjogren's syndrome or other autoimmune disease

Exclusion Criteria:

  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the run-in and duration of the study
  • Pregnancy or lactation
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00502073
ST-603-005
Not Provided
Not Provided
Sirion Therapeutics, Inc.
Not Provided
Study Chair: Roger Vogel, MD Sirion Therapeutics
Sirion Therapeutics, Inc.
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP